Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant HAIC + TACE plus lenvatinib and camrelizumab in high‑risk resectable hepatocellular carcinoma (Phase II)
ChiCTR2600119366Phase 2Not yet recruiting
- Sponsor
- Guangdong Provincial People's Hospital
- Start
- Feb 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of lenvatinib and camrelizumab in hepatocellular carcinoma (HCC), sponsored by Guangdong Provincial People's Hospital. Primary endpoint: Objective Response Rate (ORR). Planned start Feb 2026; status: not yet recruiting.
02
Drugs
lenvatinibcamrelizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2600119366.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600119366.